Cancer Vaccines: Back to the Drawing Board - Genetic Engineering News (press release) | Emerging opportunities in Beta 2 Microglobulin Testing Industry | Scoop.it
Cancer Vaccines: Back to the Drawing Board
Genetic Engineering News (press release)
To date, only one immunotherapeutic that could be considered a vaccine, Dendreon's Provenge, has gained U.S. marketing approval.